As GH secretion declines with age (somatopause), the resulting drop in IGF-1 contributes to progressive loss of lean mass
Subcutaneous injections place the peptides just beneath the skin, allowing direct absorption into the bloodstream and targeted delivery to the injury site
This is especially important in our modern world where were exposed to so many environmental toxins

Animal Research Context: Scaling from Rodents Preclinical studies with Dihexa and angiotensin IV analogues employed doses that ranged considerably depending on species, route, and outcome measured: Intravenous (IV) Administration Animal studies using intravenous dosing (which bypasses absorption barriers and achieves near-complete bioavailability) reported cognitive and neuroprotective effects at: 0.1 to 2.0 mg/kg in rodent studies (McCoy et al., 2013) Doses at the higher end of this range (12 mg/kg IV) produced robust behavioral effects For a 70 kg human, equivalent to 70140 mg total IV dose (crude extrapolation) However, direct extrapolation from rodents to humans is unreliable due to differences in metabolism, brain penetration, and receptor sensitivity Intraperitoneal (IP) Administration IP dosing (injection into the abdominal cavity, with slower absorption than IV) showed effects at: Up to 10 mg/kg in some studies Lower bioavailability than IV, requiring higher nominal doses for similar effects This route is not practical for human use Why Rodent Dosing Doesn't Directly Translate Rodent pharmacokinetics differ substantially from humans

If your provider thinks it is safe, they will teach you proper technique, needle disposal, and how to watch for side effects
The stack is less appropriate for someone whose primary interest is GHK-Cu for skin aesthetics alone without a concurrent fat-loss goal